1,079 results on '"Ugurel, Selma"'
Search Results
2. Kutane Nebenwirkungen onkologischer Systemtherapien: Schwerpunkt „Nebenwirkungsmanagement“
3. Update Merkel-Zell-Karzinom
4. Comparison of visual diagnostic accuracy of dermatologists practicing in Germany in patients with light skin and skin of color
5. Kutane Nebenwirkungen onkologischer Systemtherapien: Hand-Fuß-Syndrom und Nagelveränderungen
6. Merkel Cell Carcinoma: Integrating Epidemiology, Immunology, and Therapeutic Updates
7. CellViT: Vision Transformers for Precise Cell Segmentation and Classification
8. Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy – A multicenter study on 2419 patients from the prospective skin cancer registry ADOReg
9. Short- and long-term immunosuppressive effects of melanoma influence the prognostic value of the sentinel lymph node status
10. Early versus late response to PD-1-based immunotherapy in metastatic melanoma
11. Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomas
12. Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial
13. Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
14. Neues zum Thema Melanom: Von der Adjuvanz ab Stadium II bis zur neuartigen Therapie mit ImmTAC
15. Molekularpathologie und Biomarker des Melanoms
16. Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases
17. CellViT: Vision Transformers for precise cell segmentation and classification
18. Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma
19. Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockade
20. Effects of an immunosuppressive therapy on the efficacy of immune checkpoint inhibition in metastatic melanoma – An analysis of the prospective skin cancer registry ADOREG
21. Retraction Note: TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT
22. Ten recommendations for sarcoma surgery: consensus of the surgical societies based on the German S3 guideline “Adult Soft Tissue Sarcomas”
23. Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma – analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM
24. Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial
25. Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study
26. Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG
27. Characterisation and outcome of RAC1 mutated melanoma
28. Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma
29. Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors
30. Cutaneous Aspects of Leukemia
31. Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study
32. Clinical determinants of long-term survival in metastatic uveal melanoma
33. Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
34. Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma
35. Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events
36. Incidence and Relative Survival of Patients with Merkel Cell Carcinoma in North Rhine-Westphalia, Germany, 2008–2021
37. Clinical and genetic characteristics of BAP1-mutated non-uveal and uveal melanoma
38. Neue S1‐Leitlinie Talgdrüsenkarzinom
39. The interplay between metabolic adaptations and diet in cancer immunotherapy
40. Case report: Durable complete response of a mucosal melanoma of the rectum after neoadjuvant immunotherapy with ipilimumab plus nivolumab
41. S1‐Leitlinie Talgdrüsenkarzinom
42. Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases.
43. NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors
44. Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600 mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial
45. The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients
46. Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases
47. Computed tomography-guided biopsy of radiologically unclear lesions in advanced skin cancer: A retrospective analysis of 47 cases
48. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Dermatooncology Group
49. Leptomeningeal disease from melanoma—Poor prognosis despite new therapeutic modalities
50. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.